Treatment of Classic Hemophilia: The Use of Fibrinogen Rich in Factor VIII for Hemorrhage and for Surgery

Abstract

CLASSIC hemophilia, comprising about 80 per cent of the heritable coagulation disorders, is characterized by a hemostatic defect largely attributed to deficiency of a clot-promoting principle in the fresh plasma of affected persons. This principle, popularly known as AHG (antihemophilic globulin) or AHF (antihemophilic factor) and officially known as factor VIII, is quantitatively related to thromboplastin generation in vitro and to hemostatic efficiency in vivo. Restoration of plasma factor VIII activity to a clinically useful extent is generally accepted as the rational foundation of the specific therapy of classic hemophilia.In most cases of classic hemophilia factor VIII deficiency appears . . .